20xx年醫(yī)學(xué)專題—asco結(jié)直腸癌熱點(diǎn)薈萃北京(編輯修改稿)
2024-10-31 14:15 本頁面
【文章內(nèi)容簡介】 SEP, 2022,N = 526,第二十六頁，共六十八頁。,Patient Characteristics by Tumor Side, 80405 (KRAS wt),*Transverse colon – 66 (excluded from analysis)。 unknown 46 **Test of any liver metastases versus extrahepatic,第二十七頁，共六十八頁。,80405: Overall Survival by Sidedness,Right,Left,第二十八頁，共六十八頁。,80405: OS by Sidedness (Bevacizumab),Presented by:,Left,Right,第二十九頁，共六十八頁。,80405: OS by Sidedness (Cetuximab),Presented by:,Left,Right,第三十頁，共六十八頁。,80405: Sidedness is Prognostic Progression Free Survival (PFS),Presented by:,*Adjusted for biologic, protocol chemotherapy, prior adjuvant therapy, prior RT, age, sex , synchronous disease, in place primary, liver metastases,第三十一頁，共六十八頁。,80405: Sidedness is Prognostic Overall Survival (OS),Presented by:,*Adjusted for biologic, protocol chemotherapy, prior adjuvant therapy, prior RT, age, sex, synchronous disease, in place primary, liver metastases,19.3 MONTHS IS A BIG DIFFERENCE !!,第三十二頁，共六十八頁。,Median OS by Sidedness: 80405 and FIRE3*,KRAS wt N=1025,All RAS wt N=394,* Sebastian Stintzing,MD, personal communication Heinemann, et al, ASCO, 2022,第三十三頁，共六十八頁。,80405: Sidedness Predictive for Biologics Biologic by 1176。 Side Interaction,*Adjusted for biologic, protocol chemotherapy, prior adjuvant therapy, prior RT, age, sex, synchronous disease, in place primary, liver metastases,第三十四頁，共六十八頁。,Overall Survival by Sidedness and Biologic,第三十五頁，共六十八頁。,CALGB/SWOG 80405: Sidedness in KRAS wt mCRC,Prognostic Pts w/ Lsided primary have markedly better OS than pts w/ Rsided primary tumor regardless of treatment arm. Predictive 1stline Cetuximab and Bevacizumab have different treatment effects in subgroups defined by sidedness
規(guī)章制度相關(guān)推薦
鄂ICP備17016276號-1